Man Group
SAGE

Man Group’s Sage Therapeutics SAGE Stock Holding History

Man Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-62,900
Closed -$342K – 2339
2024
Q4 		$342K Buy
+62,900
New +$385K ﹤0.01% 1761
2024
Q3 		– Sell
-25,903
Closed -$281K – 2175
2024
Q2 		$281K Buy
+25,903
New +$332K ﹤0.01% 1802
2023
Q3 		– Sell
-80,661
Closed -$3.79M – 2119
2023
Q2 		$3.79M Buy
+80,661
New +$4.01M 0.01% 979
2023
Q1 		– Hold
0
– – – 926
2022
Q4 		– Sell
-9,053
Closed -$355K – 2181
2022
Q3 		$355K Buy
+9,053
New +$350K ﹤0.01% 1617
2022
Q2 		– Sell
-79,208
Closed -$2.65M – 960
2022
Q1 		$2.62M Buy
+79,208
New +$2.98M 0.01% 1137
2021
Q4 		– Sell
-4,603
Closed -$204K – 2082
2021
Q3 		$204K Buy
4,603
+1,095
+31% +$50.2K ﹤0.01% 1756
2021
Q2 		$200K Sell
3,508
-11,710
-77% -$828K ﹤0.01% 1805
2021
Q1 		$1.14M Sell
15,218
-33,714
-69% -$2.76M 0.01% 1259
2020
Q4 		$4.23M Sell
48,932
-79,555
-62% -$5.86M 0.02% 902
2020
Q3 		$7.85M Buy
128,487
+64,594
+101% +$3.27M 0.03% 582
2020
Q2 		$2.66M Buy
63,893
+26,577
+71% +$965K 0.01% 946
2020
Q1 		$1.07M Buy
+37,316
New +$2.16M 0.01% 1099
2019
Q4 		– Sell
-16,279
Closed -$2.28M – 1897
2019
Q3 		$2.28M Buy
16,279
+14,111
+651% +$2.36M 0.01% 1202
2019
Q2 		$397K Sell
2,168
-11,047
-84% -$1.88M ﹤0.01% 1710
2019
Q1 		$2.1M Buy
+13,215
New +$1.91M 0.01% 1315
2018
Q4 		– Sell
-15,452
Closed -$2.18M – 2090
2018
Q3 		$2.18M Buy
15,452
+10,848
+236% +$1.67M 0.01% 1388
2018
Q2 		$721K Buy
4,604
+3,205
+229% +$503K ﹤0.01% 1702
2018
Q1 		$225K Buy
+1,399
New +$238K ﹤0.01% 1902

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Man Group's SAGE Position: Q1 2025 in Review

Man Group sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 62,900 shares — an estimated $342K sold.

Man Group first reported a position in SAGE in Q1 2018 and held it in 18 quarters. The position peaked at $7.85M in Q3 2020. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Man Group reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Man Group sold 62,900 Sage Therapeutics shares in Q1 2025, an estimated $342K.
  • Man Group first reported a position in Sage Therapeutics in Q1 2018 and held it in 18 quarters.
  • Man Group's Sage Therapeutics position peaked at $7.85M in Q3 2020.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Man Group's 13F filing for Q1 2025, filed 15 May 2025.